EHBP1L1: A Potential Drug Target and Biomarker (G254102)

Target Name: EHBP1L1

NCBI ID: G254102

EHBP1L1

EHBP1L1: A Potential Drug Target and Biomarker

EHBP1L1 (EH domain-binding protein 1-like protein 1), a 14 kDa protein, was identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, expressed in various tissues and conditions, makes it an attractive target for the development of new treatments.

The EHBP1L1 protein is characterized by a 190 amino acid long EH domain, which is known for its unique flexibility and ability to interact with various protein partners. This domain is involved in the protein's unique structure and function, allowing it to interact with other proteins and molecules in the cell.

One of the most significant functions of EHBP1L1 is its role in the regulation of cell adhesion. EHBP1L1 is known to be involved in the formation of tight junctions, which are a type of cell-cell adhesion, and is vital for maintaining tissue structure and function. This is critical for various physiological processes, including embryonic development, tissue repair, and immune responses.

In neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, the loss of tight junctions is a common pathological feature. This loss of cell-cell adhesion contributes to the progression of neurodegeneration and the development of neuropsychiatric disorders. Therefore, targeting EHBP1L1 as a drug target or biomarker could potentially provide new therapeutic options for these diseases.

EHBP1L1 has also been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer. Therefore, targeting EHBP1L1 in this pathway could also imply the potential for the development of new anti-cancer drugs.

In addition to its role in cell signaling pathways, EHBP1L1 has also been shown to be involved in the regulation of inflammation. This is critical for the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Therefore, targeting EHBP1L1 as a drug target or biomarker in these diseases could potentially provide new therapeutic options for the management of these conditions.

EHBP1L1 has also been shown to be involved in the regulation of cell metabolism and metabolism-related pathways. This is critical for the development and progression of diseases, including obesity, type 2 diabetes, and cancer. Therefore, targeting EHBP1L1 in these diseases could potentially provide new therapeutic options for the management of these conditions.

In conclusion, EHBP1L1 is a protein with unique characteristics that make it an attractive target for the development of new drugs or biomarkers. Its role in the regulation of cell adhesion, signaling pathways, inflammation, and metabolism-related pathways makes it a potential drug or biomarker for a variety of diseases, including neurodegenerative diseases, autoimmune disorders, cancer, and obesity.

The identification of EHBP1L1 as a potential drug target or biomarker has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand its functions and potential as a drug or biomarker, and to develop effective strategies for its targeting.

Protein Name: EH Domain Binding Protein 1 Like 1

Functions: May act as Rab effector protein and play a role in vesicle trafficking

The "EHBP1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHBP1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets